1. Home
  2. EVAX vs RLYB Comparison

EVAX vs RLYB Comparison

Compare EVAX & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVAX
  • RLYB
  • Stock Information
  • Founded
  • EVAX 2008
  • RLYB 2018
  • Country
  • EVAX Denmark
  • RLYB United States
  • Employees
  • EVAX N/A
  • RLYB N/A
  • Industry
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • RLYB Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVAX Health Care
  • RLYB Health Care
  • Exchange
  • EVAX Nasdaq
  • RLYB Nasdaq
  • Market Cap
  • EVAX 15.1M
  • RLYB 14.4M
  • IPO Year
  • EVAX 2021
  • RLYB 2021
  • Fundamental
  • Price
  • EVAX $2.64
  • RLYB $0.41
  • Analyst Decision
  • EVAX Strong Buy
  • RLYB Hold
  • Analyst Count
  • EVAX 2
  • RLYB 3
  • Target Price
  • EVAX $10.00
  • RLYB $15.00
  • AVG Volume (30 Days)
  • EVAX 101.0K
  • RLYB 8.1M
  • Earning Date
  • EVAX 08-13-2025
  • RLYB 08-07-2025
  • Dividend Yield
  • EVAX N/A
  • RLYB N/A
  • EPS Growth
  • EVAX N/A
  • RLYB N/A
  • EPS
  • EVAX N/A
  • RLYB N/A
  • Revenue
  • EVAX $3,293,000.00
  • RLYB $848,000.00
  • Revenue This Year
  • EVAX N/A
  • RLYB N/A
  • Revenue Next Year
  • EVAX N/A
  • RLYB N/A
  • P/E Ratio
  • EVAX N/A
  • RLYB N/A
  • Revenue Growth
  • EVAX 2555.64
  • RLYB N/A
  • 52 Week Low
  • EVAX $1.20
  • RLYB $0.22
  • 52 Week High
  • EVAX $17.75
  • RLYB $1.54
  • Technical
  • Relative Strength Index (RSI)
  • EVAX 55.56
  • RLYB 55.26
  • Support Level
  • EVAX $2.26
  • RLYB $0.32
  • Resistance Level
  • EVAX $2.60
  • RLYB $0.61
  • Average True Range (ATR)
  • EVAX 0.21
  • RLYB 0.05
  • MACD
  • EVAX -0.02
  • RLYB 0.01
  • Stochastic Oscillator
  • EVAX 51.32
  • RLYB 34.82

About EVAX Evaxion Biotech

Evaxion AS is in the field of oncology. It used the AI-Immunology platform.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Share on Social Networks: